Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy: Multicenter Cohort Study

Fujian Medical University1 site in 1 country219 target enrollmentJanuary 1, 2023

ConditionsLocally Advanced Gastric Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Locally Advanced Gastric Cancer
Sponsor: Fujian Medical University
Enrollment: 219
Locations: 1
Primary Endpoint: 3-year overall survival
Status: Active, not recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To explore the effect of adjuvant chemotherapy cycles on the prognosis of this specific patient with lymph node-negative gastric cancer following neoadjuvant chemotherapy.

Detailed Description

We analyzed clinicopathological data from patients with lymph node-negative gastric cancer who underwent neoadjuvant chemotherapy at four institutions between 2010 and 2020. The 3-year OS was assessed using landmark analysis. Independent risk factors associated with 3-year OS were identified using a Cox proportional hazards regression model.

Registry

clinicaltrials.gov

Start Date

January 1, 2023

End Date

September 30, 2024

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Fujian Medical University

Responsible Party

Principal Investigator

Chang-Ming Huang, Prof.

Fujian Medical University Union Hospital

Fujian Medical University

Eligibility Criteria

Inclusion Criteria

•(1) preoperative neoadjuvant chemotherapy; (2) primary gastric adenocarcinoma, diagnosed by gastroscopic pathology findings before neoadjuvant chemotherapy in complete pathological remission (pCR) cases or via postoperative pathology findings in all other instances; (3) absence of distant metastases in the liver, lungs, or abdominal cavity, as confirmed by preoperative chest radiography or chest computed tomography (CT), abdominal ultrasonography, abdominal CT, and other imaging; (4) radical gastric cancer surgery (R0) and D2 lymph node dissection; and (5) postoperative pathologic verification of no lymph node metastasis (i.e., lymph node-negative).

Exclusion Criteria

•(1) preoperative radiotherapy or radiochemotherapy, (2) discovery of distant metastases preoperatively or intraoperatively, (3) coexistence of other malignant tumors, (4) residual gastric cancer, and (5) perioperative patient mortality.